Article
Dr. Lemack on treatments in development for OAB
In this video, Gary Lemack, MD, offers a brief overview of overactive bladder treatments in development and explains their significance for providers and patients.
Gary Lemack, MD, of UT Southwestern Medical Center in Dallas, co-authored an article in the April 2020 issue of Urology Times® regarding how the development of new pharmacological and device-based treatments could change the management of overactive bladder. In this interview, Dr. Lemack offers a brief overview of treatments in development and explains their significance for providers and patients.
Related Videos
Special Report: Tips for PCPs on evaluating prostate cancer risk
Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
Special Report: Tailoring prostate cancer care for older adults
Special Report: New strategies emerge for metastatic prostate cancer
Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC
Case 2: A 63-Year-Old Man With Recurrent HSPC
Comorbidities and Adherence: Tailoring mHSPC Treatment
Related Content
